

Olympic Therapeutics AG has been awarded the DISQTrust Growth Champion seal (valid until April 2027). The award is granted by DISQTrust, a brand of the German Institute for Service Quality, based on independent data assessment and research using publicly available sources. The results do not claim completeness and are not representative. Promotional use of the DISQTrust certificate is permitted only after lawful acquisition.

Company Assessment

From the perspective of DISQTrust, Olympic Therapeutics AG operates in a highly specialized and future-relevant market environment. According to information available on the company's website, Olympic Therapeutics AG positions itself within biopharmaceutical research and development, with a focus on innovative technologies for the treatment of MRSA and other bacterial infections using bacteriophages.

The company is active in a field situated at the intersection of healthcare, infectious disease medicine, and innovative therapy development. Based on publicly available information, Olympic Therapeutics AG has been registered as a public limited company in Zug, Switzerland, since 2008.

Given the increasing global challenge of antimicrobial resistance, the company's area of activity is considered highly relevant. The World Health Organization identifies antimicrobial resistance as a serious global health threat and explicitly highlights bacteriophages as a promising therapeutic approach, particularly for antibiotic-resistant infections such as MRSA.

Recommendation

With 17 out of 25 points in the Recommendation category, Olympic Therapeutics AG achieves a solid result that must be interpreted within its industry context. In highly specialized biopharmaceutical research environments, publicly visible consumer-style reviews play only a minor role. Market perception and trust are instead shaped primarily by scientific credibility, professional presentation, and strategic positioning.

Website Presentation

Olympic Therapeutics AG achieves an excellent score of 24 out of 25 points in the Website Presentation category. The website conveys a focused, professional, and credible impression, clearly outlining the company's strategic orientation, business model, and key personnel. This strengthens confidence and transparency, which are essential in research-driven healthcare sectors.

Online Service Elements

With a score of 23 out of 25 points, Olympic Therapeutics AG also achieves a high rating in Online Service Elements. The company appears digitally accessible and well structured, providing essential corporate information in a clear and professional manner. This supports engagement with potential partners, investors, and other stakeholders.

Customer Service

In the Customer Service category, Olympic Therapeutics AG receives 19 out of 25 points, indicating good overall service quality. Publicly available information reflects clear responsibilities and visible leadership, which enhances credibility. Further development potential exists as public interaction evolves alongside increased market presence.

Overall Evaluation – Growth Champion Context

With an overall score of 83 out of 100 points, Olympic Therapeutics AG is well positioned within the Growth Champion framework. The company's strength lies in its specialization, relevance of its medical focus, and long-term development potential rather than broad public visibility.

Conclusion and Future Potential

Olympic Therapeutics AG presents itself as a specialized and forward-looking company with a strong foundation. The focus on bacteriophage-based therapies for resistant bacterial infections provides significant future potential, particularly as global regulatory and scientific attention in this area continues to increase.

Award Announcement

Dortmund, March 2026 – Olympic Therapeutics AG has been officially recognized as Growth Champion 2026 by DISQTrust. The award honors outstanding corporate development, strategic excellence, and sustainable growth. According to Hans Balz, Director and Chairman of the Board, the distinction confirms Olympic Therapeutics AG's strategy of combining innovative bacteriophage research with a holistic approach to addressing the global antibiotic resistance crisis.